Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Cancer Lett. 2020 Nov 8;500:274–280. doi: 10.1016/j.canlet.2020.11.004

Figure 1. Preclinical Glioblastoma Targeting by FA-pRNA-3WJ-si(Luc) RNPs.

Figure 1.

(A) Schematic diagram showing sequence map of FA-pRNA-3WJ-si(Luc) RNP harboring FA (targeting ligand), Alexa647 (imaging module), and siRNA against luciferase (therapeutic module). (B) Glioblastoma targeting by FA-Alexa647-pRNA-3WJ RNP in U87EGFRvIII-induced intracranial brain tumor mice models. Tumor location and size were determined by MRI, while the specific targeting of RNPs were visualized by fluorescence intensity. (C) Representative bioluminescence intensity from intracranial glioblastoma bearing mice showing reduction of luciferase activity by systemic injection of FA-pRNA-3WJ-siRNA(Luc). (D) Biodistribution profile of FA-Alexa647-pRNA-3WJ RNP obtained from major internal organs collected from intracranial brain tumor bearing mice 15 hours after systemic injection through tail vein. All figures were adapted from Lee et al., 2015 [68].